Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains bullish on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX). On February 25, EPRX announced what it described as positive data from its RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis. “In the RESOLVE trial, […]
Buy the stock on weakness. That’s the advice from Raymond James analyst Michael W. Freeman on Profound Medical Corp. (Profound Medical Stock Quote, Chart, News, Analysts, Financials NASDAQ:PROF). “Here we address recent weakness in PROF stock and highlight catalysts to expect through 2025,” the analyst wrote. “PROF was down (18%) vs. Nasdaq (0.2%) since the […]
Share
Tweet
Share
